Article Text

Download PDFPDF
Serum copeptin: a potential guide to clinical decision-making for congenital shunt closure
  1. Kenan Yalta,
  2. Muhammet Gurdogan,
  3. Caglar Kaya,
  4. Utku Zeybey
  1. Cardiology Department, Trakya Universitesi, Edirne, Turkey
  1. Correspondence to Professor Kenan Yalta, Cardiology Department, Trakya Universitesi, Edirne, Turkey; kyalta{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor In clinical practice, pulmonary arterial hypertension (PAH) associated with congenital cardiac shunts may possibly progress to end-stage pulmonary arterial vasculopathy even after successful shunt closure potentially leading to substantially worse prognosis in certain settings.1 In their recently published article, van der Feen et al have discussed a variety of modalities in assessing the reversibility of PAH in the setting of congenital heart disease (CHD).1 We agree on the potential utility of most of these modalities along with the limited, value of well-known biomarkers including natriuretic peptides in this setting.1 On the other hand, we hold the opinion …

View Full Text


  • Contributors All the authors have significantly contributed to this work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.